Longeveron shares jump 13.05% premarket as Alzheimer's treatment data selected for CTAD 2025 poster presentation.

Longeveron Inc. surged 13.05% in premarket trading following the announcement that its laromestrocel (Lomecel-B) data in Alzheimer’s disease was selected for a poster presentation at the 18th Clinical Trials on Alzheimer’s Disease Conference (CTAD 2025). The poster, titled “Reduced brain neuroinflammation after laromestrocel treatment in mild AD: results from the CLEAR MIND study,” highlights preliminary findings from its Phase 2 trial, suggesting the therapy may reduce neuroinflammation in mild Alzheimer’s. The company emphasized that the selection at CTAD—a leading forum for Alzheimer’s research—validates its cellular-based approach and positions laromestrocel as a potential regenerative therapy. The news aligns with Longeveron’s broader strategy to advance its Alzheimer’s program, which has already received RMAT and Fast Track designations from the FDA. The stock’s sharp rise reflects investor optimism about the clinical visibility and potential therapeutic value of its stem cell therapy.